← Leaderboards
Minesh P. Mehta
University Of Wisconsin Madison
$1,459,043
Attributed
$1,459,043
Total exposure
18
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–08$2M$1.5M$1M$500K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$10,368,882 · 19
By mechanism
P01$8,909,839 · 2
U01$873,060 · 1
M01$585,983 · 15
P20$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- George Wilding$32,976,854
- Mark A Ritter$3,944,709
- William R. Engels$5,685,373
- Peiman Hematti$1,747,674
- Judith N Burstyn$2,941,784
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectClinical ResearchNeoplasm /Cancer Radiation TherapyGliomaDrug Screening /EvaluationNeoplasm /Cancer ChemotherapyClinical Trial Phase IBrain NeoplasmsPharmacokineticsPatient Oriented ResearchAntineoplasticsDrug Adverse EffectClinical Trial Phase IiMagnetic Resonance ImagingGadoliniumRadiosensitizerTissue Resource /RegistryComputed Axial TomographyFundingCarboplatinCooperative StudyDosageAnticonvulsants
Grant awards (44)
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$122,873
U01 · FY2008 · CA · contact PI
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$121,906
U01 · FY2007 · CA · contact PI
PHASE I/II STUDY OF OSI-774 AND CCI-779 IN RECURRENT MALIGNANT GLIOMA$4,859
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF XRT + LOW-DOSE TEMOZOLOMIDE FOLLOWED BY TEMOZOLOMIDE + CPT-11$949
M01 · FY2007 · RR · contact PI
PHASE II TRIAL OF EMD 121974 FOR RECURRENT GLIOBLASTOMA$491
M01 · FY2007 · RR · contact PI
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$122,142
U01 · FY2006 · CA · contact PI
PHASE II STUDY OF XRT + LOW-DOSE TEMOZOLOMIDE FOLLOWED BY TEMOZOLOMIDE + CPT-11$11,171
M01 · FY2006 · RR · contact PI
PHASE I/II STUDY OF OSI-774 AND CCI-779 IN RECURRENT MALIGNANT GLIOMA$3,414
M01 · FY2006 · RR · contact PI
PHASE I/II TRIAL OF CPT-11 AND TEMOZOLOMIDE IN RECURRENT MALIGNANT GLIOMA$931
M01 · FY2006 · RR · contact PI
Improving Cancer Outcome--Adaptive Helical Tomotherapy$1,844,141
P01 · FY2005 · CA
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$125,604
U01 · FY2005 · CA
PHASE I/II TRIAL OF CPT-11 AND TEMOZOLOMIDE IN RECURRENT MALIGNANT GLIOMA$17,977
M01 · FY2005 · RR
PHASE I/II TRIAL OF R115777 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA$1,498
M01 · FY2005 · RR
Improving Cancer Outcome--Adaptive Helical Tomotherapy$1,790,419
P01 · FY2004 · CA
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$125,892
U01 · FY2004 · CA
Phase I/II Trial of CPT-11 and Temozolomide in Recurrent Malignant Glioma$57,198
M01 · FY2004 · RR
Phase I/II OSI-774 in Recurrent Malignant Gliomas and Malignant Gliomas Post XRT$14,443
M01 · FY2004 · RR
Phase I/II ZD1839 in Astrocytoma or Glioblastoma and Meningioma$3,467
M01 · FY2004 · RR
Phase I Study of ZD 1839 and Temozolomide for the Treatment of Gliomas$2,310
M01 · FY2004 · RR
Phase I/II Trial of R115777 in Patients with Recurrent Malignant Glioma$2,310
M01 · FY2004 · RR
Improving Cancer Outcome--Adaptive Helical Tomotherapy$1,738,270
P01 · FY2003 · CA
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$66,508
U01 · FY2003 · CA
Improving Cancer Outcome--Adaptive Helical Tomotherapy$1,697,990
P01 · FY2002 · CA
PHASE II TRIAL OF THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLI$106,600
M01 · FY2002 · RR
PHASE IB/II TRIAL OF PC 0120AS RADIOSENSITIZER IN METASTATIC BRAIN CANCER$106,600
M01 · FY2002 · RR
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$64,575
U01 · FY2002 · CA
TOMOTHERAPY BASED ON FUNCTIONAL MRI$0
P20 · FY2002 · CA
TOMOTHERAPY BASED DOSE PER FRACTION ESCALATION IN NSCLC$0
P01 · FY2002 · CA
Improving Cancer Outcome--Adaptive Helical Tomotherapy$1,839,019
P01 · FY2001 · CA
PHASE II TRIAL OF THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLI$106,600
M01 · FY2001 · RR
PHASE IB/II TRIAL OF PC 0120AS RADIOSENSITIZER IN METASTATIC BRAIN CANCER$106,600
M01 · FY2001 · RR
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$62,693
U01 · FY2001 · CA
PHASE IB/II TRIAL OF PC 0120AS RADIOSENSITIZER IN METASTATIC BRAIN CANCER$12,855
M01 · FY2001 · RR
PHASE II TRIAL OF THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLI$12,855
M01 · FY2001 · RR
TOMOTHERAPY BASED DOSE PER FRACTION ESCALATION IN NSCLC$0
P01 · FY2001 · CA
TOMOTHERAPY BASED ON FUNCTIONAL MRI$0
P20 · FY2001 · CA
NABTC (UCSF PROJECT LEADER) U OF WISCONSIN$60,867
U01 · FY2000 · CA
PHASE IB/II TRIAL OF PC 0120AS RADIOSENSITIZER IN METASTATIC BRAIN CANCER$12,855
M01 · FY2000 · RR
GADOLINIUM TEXAPHYRIN (PCI-0120) RADIATION SENSITIZER IN WHOLE BRAIN RADIATION TH$0
M01 · FY2000 · RR
PHASE II TRIAL OF THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLI$0
M01 · FY2000 · RR
TRIAL OF IRINOTECAN IN PTS W RECURRENT MALIGNANT GLIOMA$0
M01 · FY2000 · RR
TRIAL OF IRINOTECAN IN PTS W RECURRENT MALIGNANT GLIOMA$0
M01 · FY2000 · RR
PHASE II TRIAL OF THYMIDINE &CARBOPLATIN FOR RECURRENT MALIGNANT GLI$0
M01 · FY2000 · RR
GADOLINIUM TEXAPHYRIN (PCI-0120) RADIATION SENSITIZER IN WHOLE BRAIN RADIATION TH$0
M01 · FY2000 · RR